Redwood AI Launches Collaborative Research Project with UBC's Brent Page Lab Focused on Alzheimer's Drug Discovery

Executive Summary

• Redwood AI Corp. announced a collaborative research project with the Brent Page Lab at the University of British Columbia to develop novel Alzheimer’s disease therapeutics targeting NUDT5.
• The partnership leverages Redwood’s AI‑driven drug design platform and the lab’s medicinal chemistry expertise to generate and prioritize virtual compound libraries for early‑stage discovery.
• CEO Louis Dron highlighted the strategic importance of AI in accelerating drug discovery and indicated potential long‑term applicability across multiple disease areas.

Key Details

• Project Title: “Novel Therapeutics for Neurodegeneration – Targeting NUDT5 in Alzheimer’s Disease.”
• Objective: Design and optimize inhibitors of NUDT5, a protein implicated in neurodegenerative signaling pathways.
• Redwood AI Role: Apply computational platform to create synthetically tractable virtual libraries, evaluate safety/efficacy profiles in‑silico, and prioritize candidates for synthesis.
• Brent Page Lab Role: Conduct experimental validation (synthesis, biochemical assays, molecular docking) of AI‑selected compounds.
• Target Disease Impact: Addresses a major unmet medical need—over 55 million people worldwide living with dementia; aims to shorten early discovery timelines and improve preclinical candidate quality.
• Strategic Rationale (CEO Quote): “AI will play an increasingly central role in how new medicines are discovered… Programs like this one are building a foundation for a faster, more efficient approach to therapeutic innovation.”

Notable Quotes

• Louis Dron, CEO, Redwood AI: “We believe AI will play an increasingly central role in how new medicines are discovered and developed over the next decade. By pairing advanced computational design with world‑class academic science, we aim to help shorten the path from early discovery to stronger preclinical candidates.”